Biotechnology

MoonLake Immunotherapeutics

Moonlake Immunotherapeutics' CSO reports sale of common stock

MoonLake Immunotherapeutics CEO Plans to Sell 200,000 Restricted Shares

Retail Traders Optimistic Ahead of MoonLake Therapeutics Summit

MoonLake Immunotherapeutics Receives Hold Rating from Analysts, Major Shareholder Reduces Holdings

MoonLake Immunotherapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.1003 (forecast USD -0.8816)

MoonLake Immunotherapeutics released FY2025 9 Months earnings on November 5 (EST), actual revenue USD 0, actual EPS USD -2.6046

Serge Belanger gives MoonLake SLK project a buy rating

MoonLake Immunotherapeutics to Issue Shares to Raise Funds

MoonLake Immunotherapeutics Reports Q3 2025 Financials Missing Estimates

MoonLake Immunotherapeutics Announces Q3 2025 Financial Results and Positive Clinical Trial Results for Sonelokimab

Analyst Argyrides Focuses on Healthcare Industry and Recommends Stocks

Rosen Advises MoonLake Immunotherapeutics Investors to Seek Legal Counsel for Class Action

MoonLake Immunotherapeutics Shares Plunge, Hagens Berman Launches Investigation

Moonlake Immunotherapeutics CFO Acquires Company Common Stock

H.C. Wainwright downgrades MoonLake Immunotherapeutics to hold

Bihua Chen Sells Shares of Moonlake Immunotherapeutics

MoonLake Immunotherapeutics Investigated After Near 90% Stock Plunge

Rami Katkhuda Gives MoonLake Immunotherapeutics a Buy Rating

MoonLake Immunotherapeutics reports positive results for sonelokimab in Phase 3 trial for axillary hidradenitis suppurativa

MoonLake Immunotherapeutics released FY2025 Q2 earnings on August 5, 2025 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD -0.8725 (forecast USD -0.7141)

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap